Artios Raises £87m Series D Funding to Target Cancers via DNA

Artios raises £87m Series D funding to target cancers via DNA

Artios Pharma, a biopharmaceutical company targeting cancers, has raised £87 million in Series D funding. The Cambridge MedTech, aiming to realise the therapeutic power of targeting the DNA damage response in cancer, said the oversubscribed financing would enable it to expand the clinical evaluation of its lead program, alnodesertib, to enrol additional patients in each of second-line pancreatic cancer and third-line colorectal cancer. The progr…

Biotech firm Artios closes oversubscribed £87m Series D

Artios, a Cambridge-based biotech group researching how to target the DNA damage response (DDR) in cancer, has successfully closed an oversubscribed $115m (£87.3m) Series D round. The new funding will support the firm’s lead programme, called alnodesertib, which is examining therapies for pancreatic and colorectal cancers. With the Series D closed, Artios can also initiate the second phase of clinical trials for its treatment targeting breast ca…